OriCell Therapeutics Co., Ltd. is advancing Ori-C101, a GPC3-directed CAR-T therapy, through a Phase Ib/II trial targeting advanced hepatocellular carcinoma (HCC). Given the high unmet medical need in HCC, particularly among patients with unresectable disease and limited treatment options, successful outcomes could position Ori-C101 as a competitive therapeutic option in a market with significant growth potential. The trial's focus on safety and preliminary efficacy will be critical for attracting partnerships or investment, especially as the CAR-T landscape becomes increasingly competitive with established players. The estimated enrollment of 105 patients across multiple centers in China indicates a robust approach to data generation, which may enhance the asset's attractiveness for future commercialization.